BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo..

BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.

BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.

BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM..

BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM.

BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM.

BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM.

BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination.

BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2.

BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

BAY-958 (BAY958, LDC526) is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.

BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM).

BAY-7598 (BAY7598) is a potent, selective MMP12 inhibitor..

BAY-707 is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM.

BAY-678 racemate is a chemical probe candidate for Human Neutrophil Elastase (HNE).

BAY-524 (BAY524) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 450 nM.

BAY-386 (BAY386) is a potent, specific and reversible PAR-1 antagonist with IC50 of 10 nM (HEK cell) and binding IC50 of 56 nM, without affinity for PAR-4 (IC50>10 uM).

BAY-320 (BAY320) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 680 nM.

BAY-293 racemate (BAY293 racemate) is a potent SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 50 nM, the R-enantiomer (BAY-293) is the active form with IC50 of 21 nM, while the BAY-293 is less active (IC50=2,340 nM)..

BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.

BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM.

BAY 60-6583 (BAY606583) is a potent, selective adenosine A2B receptor agonist with EC50 of 2.83 nM (murine A2BR).

BAY 60-2770 is an NO-independent activator of sGC (soluble guanylyl cyclase) with EC50 of 5.4 nM.

BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM).

Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

BAY 1238097 is a novel BET bromodomain inhibitor with IC50 of 50 nM, inhibits the interaction between BRD4, BRD3 or BRD2 and H4 with IC50 values of 63 nM, 609 nM and 2430 nM in the NanoBRET assay.

BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM.

BAY 1143269 is a potent, selective, orally bioavailable inhibitor of MNK1 with enzyme IC50 of 40 nM at 2 mM ATP.